No Data
Individual Investors Are Keymed Biosciences Inc.'s (HKG:2162) Biggest Owners and Were Rewarded After Market Cap Rose by HK$400m Last Week
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
【Brokerage Focus】Guosen maintains an "Outperform" rating on CanSino (02162), stating that Siponimod is expected to have a first-mover advantage.
Jinwu Finance News | Guosen Securities Research pointed out that recently, Connoa (02162) received approval for the new indication of Supilumab for the treatment of seasonal allergic rhinitis, becoming the first IL4R monoclonal antibody globally approved for this treatment. This approval is based on a multicenter, randomized, double-blind, placebo-controlled phase 3 study, which showed that during the pollen season, compared to the standard treatment group (nasal steroid + antihistamines), after 2 weeks of treatment with Supilumab, patients experienced effective control of typical nasal allergy symptoms (runny nose, nasal congestion, nasal itching, sneezing), with significant differences between the groups.
Hong Kong stock movement | Kangnuo Ya (02162) rises over 4% as the seasonal allergic rhinitis IL-4Rα biological agent Sipuqibai monoclonal antibody is approved for market.
Conoya (02162) rose by more than 4%. As of the time of this report, it increased by 4.11%, reaching HKD 32.9, with a transaction volume of 8.4294 million HKD.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
